Role of interleukin 1 beta in esophageal squamous cell carcinoma

Miao Fen Chen, Ming Shian Lu, Ping Tsung Chen, Wen Cheng Chen, Paul Yang Lin, Kuan Der Lee

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Interleukin (IL)-1 beta has been reported to be a marker of shorter survival in gastric and colorectal adenocarcinoma. In the present study, we examined the potential role and prognostic value of IL-1 beta in esophageal squamous cell carcinoma (SCC). Human esophageal SCC cell line, CE81T, was selected for cellular and animal experiments, in which biological changes after experimental manipulation of IL-1 beta signaling were explored, including tumor growth, invasion capacity, and the sensitivity to treatment. Moreover, 147 esophageal SCC samples were analyzed using immunohistochemical staining to correlate the expression of IL-1 beta with clinical outcome. Our data revealed that IL-1 beta was significantly overexpressed both at mRNA and protein levels in cancer specimens compared to nonmalignant tissues. When IL-1 beta signaling was blocked, tumor growth, invasion ability, and treatment resistance were attenuated. Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer. The immunochemistry findings indicate that positivity staining of IL-1 beta correlated significantly with higher clinical stage, lower response rate to concurrent chemoradiotherapy (CCRT), and higher recurrence rate after curative treatment. Moreover, IL-1 beta was a significant predictor of survival in patients undergoing surgical intervention or definite CCRT. In conclusion, IL-1 beta is significantly linked to poor prognosis for patients with esophageal cancer and may be a promising molecular target for therapeutic intervention for esophageal SCC.

Original languageEnglish
Pages (from-to)89-100
Number of pages12
JournalJournal of Molecular Medicine
Volume90
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Fingerprint

Interleukin-1beta
Chemoradiotherapy
Esophageal Neoplasms
Neoplasms
Growth
Esophageal Squamous Cell Carcinoma
Staining and Labeling
Immunochemistry
Epithelial-Mesenchymal Transition
Survival
NF-kappa B
Therapeutics
Stomach
Adenocarcinoma
Recurrence
Cell Line
Messenger RNA

Keywords

  • Esophageal squamous cell carcinoma
  • IL-1 beta
  • NF-κB
  • Prognosis
  • UCP

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Role of interleukin 1 beta in esophageal squamous cell carcinoma. / Chen, Miao Fen; Lu, Ming Shian; Chen, Ping Tsung; Chen, Wen Cheng; Lin, Paul Yang; Lee, Kuan Der.

In: Journal of Molecular Medicine, Vol. 90, No. 1, 01.2012, p. 89-100.

Research output: Contribution to journalArticle

Chen, Miao Fen ; Lu, Ming Shian ; Chen, Ping Tsung ; Chen, Wen Cheng ; Lin, Paul Yang ; Lee, Kuan Der. / Role of interleukin 1 beta in esophageal squamous cell carcinoma. In: Journal of Molecular Medicine. 2012 ; Vol. 90, No. 1. pp. 89-100.
@article{bc6797adbf434e93a4be2eb406d570cf,
title = "Role of interleukin 1 beta in esophageal squamous cell carcinoma",
abstract = "Interleukin (IL)-1 beta has been reported to be a marker of shorter survival in gastric and colorectal adenocarcinoma. In the present study, we examined the potential role and prognostic value of IL-1 beta in esophageal squamous cell carcinoma (SCC). Human esophageal SCC cell line, CE81T, was selected for cellular and animal experiments, in which biological changes after experimental manipulation of IL-1 beta signaling were explored, including tumor growth, invasion capacity, and the sensitivity to treatment. Moreover, 147 esophageal SCC samples were analyzed using immunohistochemical staining to correlate the expression of IL-1 beta with clinical outcome. Our data revealed that IL-1 beta was significantly overexpressed both at mRNA and protein levels in cancer specimens compared to nonmalignant tissues. When IL-1 beta signaling was blocked, tumor growth, invasion ability, and treatment resistance were attenuated. Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer. The immunochemistry findings indicate that positivity staining of IL-1 beta correlated significantly with higher clinical stage, lower response rate to concurrent chemoradiotherapy (CCRT), and higher recurrence rate after curative treatment. Moreover, IL-1 beta was a significant predictor of survival in patients undergoing surgical intervention or definite CCRT. In conclusion, IL-1 beta is significantly linked to poor prognosis for patients with esophageal cancer and may be a promising molecular target for therapeutic intervention for esophageal SCC.",
keywords = "Esophageal squamous cell carcinoma, IL-1 beta, NF-κB, Prognosis, UCP",
author = "Chen, {Miao Fen} and Lu, {Ming Shian} and Chen, {Ping Tsung} and Chen, {Wen Cheng} and Lin, {Paul Yang} and Lee, {Kuan Der}",
year = "2012",
month = "1",
doi = "10.1007/s00109-011-0809-4",
language = "English",
volume = "90",
pages = "89--100",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Role of interleukin 1 beta in esophageal squamous cell carcinoma

AU - Chen, Miao Fen

AU - Lu, Ming Shian

AU - Chen, Ping Tsung

AU - Chen, Wen Cheng

AU - Lin, Paul Yang

AU - Lee, Kuan Der

PY - 2012/1

Y1 - 2012/1

N2 - Interleukin (IL)-1 beta has been reported to be a marker of shorter survival in gastric and colorectal adenocarcinoma. In the present study, we examined the potential role and prognostic value of IL-1 beta in esophageal squamous cell carcinoma (SCC). Human esophageal SCC cell line, CE81T, was selected for cellular and animal experiments, in which biological changes after experimental manipulation of IL-1 beta signaling were explored, including tumor growth, invasion capacity, and the sensitivity to treatment. Moreover, 147 esophageal SCC samples were analyzed using immunohistochemical staining to correlate the expression of IL-1 beta with clinical outcome. Our data revealed that IL-1 beta was significantly overexpressed both at mRNA and protein levels in cancer specimens compared to nonmalignant tissues. When IL-1 beta signaling was blocked, tumor growth, invasion ability, and treatment resistance were attenuated. Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer. The immunochemistry findings indicate that positivity staining of IL-1 beta correlated significantly with higher clinical stage, lower response rate to concurrent chemoradiotherapy (CCRT), and higher recurrence rate after curative treatment. Moreover, IL-1 beta was a significant predictor of survival in patients undergoing surgical intervention or definite CCRT. In conclusion, IL-1 beta is significantly linked to poor prognosis for patients with esophageal cancer and may be a promising molecular target for therapeutic intervention for esophageal SCC.

AB - Interleukin (IL)-1 beta has been reported to be a marker of shorter survival in gastric and colorectal adenocarcinoma. In the present study, we examined the potential role and prognostic value of IL-1 beta in esophageal squamous cell carcinoma (SCC). Human esophageal SCC cell line, CE81T, was selected for cellular and animal experiments, in which biological changes after experimental manipulation of IL-1 beta signaling were explored, including tumor growth, invasion capacity, and the sensitivity to treatment. Moreover, 147 esophageal SCC samples were analyzed using immunohistochemical staining to correlate the expression of IL-1 beta with clinical outcome. Our data revealed that IL-1 beta was significantly overexpressed both at mRNA and protein levels in cancer specimens compared to nonmalignant tissues. When IL-1 beta signaling was blocked, tumor growth, invasion ability, and treatment resistance were attenuated. Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer. The immunochemistry findings indicate that positivity staining of IL-1 beta correlated significantly with higher clinical stage, lower response rate to concurrent chemoradiotherapy (CCRT), and higher recurrence rate after curative treatment. Moreover, IL-1 beta was a significant predictor of survival in patients undergoing surgical intervention or definite CCRT. In conclusion, IL-1 beta is significantly linked to poor prognosis for patients with esophageal cancer and may be a promising molecular target for therapeutic intervention for esophageal SCC.

KW - Esophageal squamous cell carcinoma

KW - IL-1 beta

KW - NF-κB

KW - Prognosis

KW - UCP

UR - http://www.scopus.com/inward/record.url?scp=84857364184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857364184&partnerID=8YFLogxK

U2 - 10.1007/s00109-011-0809-4

DO - 10.1007/s00109-011-0809-4

M3 - Article

C2 - 21912958

AN - SCOPUS:84857364184

VL - 90

SP - 89

EP - 100

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 1

ER -